Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics

Published: Saturday, February 15, 2014
Last Updated: Saturday, February 15, 2014
Bookmark and Share
Event follows collaboration to develop tools for analysis of biologics, vaccines.

Agilent Technologies Inc. has announced support for the inaugural Singapore-South Korea Symposium on Glycomics, where scientists and researchers from both nations will work toward developing biomarkers for diseases, biopharmaceuticals and therapeutic antibody products through glycomics, the study of complex sugars. The symposium will be held Feb. 12-13 in Singapore.

"This joint symposium marks increasing collaboration with our partners from South Korea in the field of glycomics, with the aim to establish Singapore and South Korea as Asian leaders in glycomics research," said professor Lam Kong Peng, executive director of the Bioprocessing Technology Institute (BTI) at the Agency for Science, Technology and Research (A*STAR). "Singapore has developed biomedical sciences as a key pillar of our economy-these collaborations will further boost Singapore's reputation as a world-class destination for biologics manufacturing and R&D."

The symposium is organized by BTI; the Korea Basic Science Institute (KBSI), one of South Korea's foremost research institutions; and Chungnam National University's Graduate School of Analytical Science and Technology (GRAST), one of South Korea's top universities and a highly regarded research leader in the field of glycomics. KBSI will lead a delegation of 35 scientists and postgraduate students from South Korea to Singapore for the symposium.

"We believe science is integral to our everyday lives, helping us to stay safe and improve our well-being," said Dr. Kwanghwa Chung, president of KBSI. "KBSI is moving forward to be an open and global science research institution, and we are committed to ongoing research and collaboration with notable organizations in Singapore, such as the Bioprocessing Technology Institute."

"GRAST leads the way in developing the biosimilars industry in South Korea," said professor Hee-Sun Chung, dean of GRAST. "We are the only graduate school in South Korea that leverages the synergistic efforts of education and research. We welcome opportunities for our researchers and students to share our work in the field of glycomics and contribute to the discovery of new cures, more effective drugs and vaccines to treat serious medical conditions."

"Agilent has long been the champion of innovation, driving developments and collaborations among members of scientific community," said Dr. Rudolf Grimm, Agilent's director of science and technology and manager of collaborations in the Asia-Pacific region. "We are committed to helping top scientists who work in the important field of glycomics and biopharmaceuticals in Singapore and South Korea to pave the way for discoveries and developments that will help people live better and longer, safely."

In Singapore, BTI is Agilent's reference site in Southeast Asia for the use of the unique mAb-Glyco NanoChip Technology. BTI is home to a number of sophisticated bio-analytical instruments including the Agilent 6550 iFunnel Ultra High Accurate Mass Q-TOF LC/MS which contains the HPLC-Chip breakthrough technology for glycoprotein analysis.

The symposium follows a number of research collaboration initiatives by Agilent in the field of glycomics, which include, among others:

• 2011 - Collaboration with Chungnam National University to develop new applications, methods, technologies and software tools in the field of glycomics.
• 2013 - Establishment of the Asia Glycomics Education, located in GRAST, to support collaborative university/industry education and cross-training. The university will develop and administer training programs for various methods of glycan analysis, which will be made available without charge to scientists and researchers endorsed by Agilent in South Korea and the South Asia-Pacific region.
• 2013 - Memorandum of understanding signed between Agilent, the Glyco-MEV laboratory at the University of Rouen, France, and the Bioprocessing Technology Institute. The three parties plan to develop tools that will analyze biologics and vaccines to ensure they are safe and effective.
• Collaborations with U.C. Davis, Boston University School of Medicine, Macau University of Science and Technology and Macquarie University in Sydney.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent and Seoul National University Hospital Collaborate
The strategic collaboration will focus on the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
Friday, October 18, 2013
Agilent Technologies and SomaLogic Enter Agreement
The agreement will expand access to SomaLogic's unbiased protein biomarker discovery platform.
Tuesday, August 13, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Agilent and Applied Proteomics Will Collaborate
Collaboration to maximize capabilities of highly multiplexed protein assays.
Friday, March 08, 2013
Agilent Collaborating with Florida International University
Collaboration to further advance the identification and characterization of designer drugs.
Tuesday, February 26, 2013
Agilent Technologies and Ameritox Form Collaboration
Agilent Technologies Inc. and AmeritoxSM announced that they have formed a research collaboration that could accelerate analysis in the field of medication monitoring.
Tuesday, February 12, 2013
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Technologies Reports Second-Quarter 2012 Results
Third-quarter fiscal year 2012 revenue guidance of $1.77 billion - $1.79 billion and non-GAAP earnings guidance of $0.82 - $0.84 per share.
Wednesday, May 16, 2012
Agilent and Integrated Diagnostics Enter Strategic Partnership
The partnership will develop protein-based assays for early disease detection.
Wednesday, January 11, 2012
Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research
The university aims to identify and develop biomarkers for diseases.
Friday, August 26, 2011
Agilent Technologies and A*STAR’s ETC Launch All-in-One Drug-Screening Platform at Singapore Screening Centre
Agilent to provide a full spectrum of automation technologies to biomedical researchers, enabling highly efficient drug screening in one location.
Tuesday, August 02, 2011
Agilent Acquires BIOCIUS Life Sciences
Agilent Technologies Inc. announces that it has acquired BIOCIUS Life Sciences, Inc., developer of the unique RapidFire™ high-throughput mass spectrometry drug-screening platform for the pharmaceutical and biopharmaceutical markets.
Thursday, March 03, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos